KPTI logo

KPTI
Karyopharm Therapeutics Inc

7,804
Mkt Cap
$50.29M
Volume
167,929.00
52W High
$14.24
52W Low
$3.51
PE Ratio
-0.40
KPTI Fundamentals
Price
$5.80
Prev Close
$5.96
Open
$5.97
50D MA
$6.35
Beta
1.20
Avg. Volume
96,540.86
EPS (Annual)
-$9.41
P/B
-0.21
Rev/Employee
$520,562.72
Loading...
Loading...
News
all
press releases
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OmniAb, Inc. (OABI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·6d ago
News Placeholder
More News
News Placeholder
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 PR Newswire NEWTON, Mass., Oct. 27, 2025...
PR Newswire·7d ago
News Placeholder
Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·17d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +3.70% and +4.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -5.74% and +0.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Zacks·5mo ago
News Placeholder
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
Zacks·6mo ago

Latest KPTI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.